ACE Inhibitor Qbrelis Gets FDA Approval
Silvergate announced that the Food and Drug Administration (FDA) has approved Qbrelis (lisinopril) Oral Solution for the treatment of hypertension in patients aged ≥6 years, as adjunct therapy for heart failure, and for the treatment of acute myocardial infarction in adults.
Qbrelis is the first oral solution formulation of lisinopril. The ready-to-use oral solution allows weight-based dosing for children ≥6 years who have had to rely on modified adult doses. Patients with swallowing difficulties may also benefit from Qbrelis Oral Solution.
Lisinopril is an ACE inhibitor that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. The effects of lisinopril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II which leads to decreased vasopressor activity and to decreased aldosterone secretion.
Qbrelis Oral Solution will be available as a 1mg/mL strength solution with a sweet taste in 150mL bottles.
For more information call (855) 379-0382 or visit SilvergatePharma.com.